| Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | |
|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||
Net loss | ||||||
-14,722 | -47,510 | -33,575 | -84,054 | -38,816 | -6,938 | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Acquired in-process research and development | ||||||
- | - | - | - | 2,157 | 0 | |
Stock-based compensation expense | ||||||
4,913 | 7,118 | 8,476 | 8,592 | 7,130 | 1,025 | |
Depreciation and amortization expense | ||||||
990 | 1,162 | 991 | 1,840 | 2,043 | 313 | |
Impairment of intangible assets | ||||||
- | 7,448 | 7,942 | 43,398 | - | - | |
Gain on sale of marketable securities | ||||||
- | - | - | 3,874 | - | - | |
Gain on deconsolidation of a variable interest entity | ||||||
- | - | 276 | - | - | - | |
Non-cash interest expense | ||||||
1,018 | 512 | 478 | 129 | 41 | 23 | |
Creditor fees | ||||||
- | - | - | 150 | - | - | |
Market value adjustments to inventories | ||||||
2,650 | 741 | 5,186 | - | - | - | |
Change in fair value of contingent consideration | ||||||
- | - | - | -1,248 | -133 | 305 | |
Change in fair value of derivative instruments | ||||||
- | - | - | 1,274 | 465 | - | |
(Gain) loss on disposition of property and equipment | ||||||
- | 30 | -2 | - | 0 | - | |
Deferred tax benefit | ||||||
- | - | - | -1,698 | -1,443 | -12,722 | |
Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | ||||||
-202 | 2,319 | 27 | -281 | 102 | - | |
Inventories | ||||||
499 | 3,187 | 15,010 | 879 | 372 | - | |
Prepaid expenses and other current assets | ||||||
185 | -335 | 771 | 595 | 642 | - | |
Prepaid expenses | ||||||
- | - | - | - | - | 249 | |
Other assets | ||||||
-188 | -88 | 5 | 31 | 45 | 14 | |
Accounts payable | ||||||
-6,540 | 62 | 6,182 | -117 | -1,143 | 1,527 | |
Accrued expenses and other liabilities | ||||||
924 | -2,605 | 2,084 | 1,185 | 482 | 579 | |
Licensing and collaboration commitment | ||||||
-200 | - | 7,000 | - | - | - | |
Net cash used in operating activities | ||||||
-11,261 | -38,185 | -11,323 | -38,495 | - | - | |
Deferred income | ||||||
- | - | - | - | -880 | - | |
Net cash provided by (used in) operating activities | ||||||
- | - | - | - | -32,188 | -16,151 | |
Cash flows from investing activities | ||||||
Milestone payments for intangible assets | ||||||
- | 6,000 | 1,000 | - | - | - | |
Purchases of property and equipment, net | ||||||
- | 1 | 72 | 2,245 | 471 | 94 | |
Cash paid for acquisitions, net of cash received | ||||||
- | - | - | - | 12,075 | 30,994 | |
Proceeds from sales of marketable securities | ||||||
- | - | - | 7,456 | - | - | |
Purchase of investments | ||||||
4,218 | 3,731 | 229,836 | 2,050,594 | 371,449 | 5,169 | |
Proceeds from maturities of investments | ||||||
3,725 | 3,980 | 288,287 | 2,079,396 | 286,670 | 6,881 | |
Cash contributed as investment in a noncontrolled entity | ||||||
- | - | 94 | - | - | - | |
Net cash provided by investing activities | ||||||
-493 | -5,752 | 57,285 | 34,013 | - | - | |
Purchase of derivative instruments | ||||||
- | - | - | - | 643 | - | |
Purchase of in-process research and development | ||||||
- | - | - | - | 2,157 | - | |
Change in restricted cash | ||||||
- | - | - | - | - | -141 | |
Net cash provided by (used in) investing activities | ||||||
- | - | - | - | -100,125 | -29,235 | |
Cash flows from financing activities | ||||||
Payments for debt issuance costs | ||||||
- | 210 | - | - | - | - | |
Proceeds from issuance of loans payable, net of discount | ||||||
- | - | - | 24,779 | - | 14,914 | |
Payments on loans payable | ||||||
36,500 | 3,500 | - | - | - | - | |
Payment for loans payable final payment fee, termination fee and other fees | ||||||
1,343 | 165 | - | - | - | - | |
Taxes paid for awards vested under equity incentive plans | ||||||
68 | 19 | - | 7 | - | - | |
Repurchase of common stock | ||||||
- | - | - | - | 1,081 | - | |
Proceeds from stock option exercises | ||||||
15 | 247 | 138 | 312 | 225 | 153 | |
Proceeds from issuance of common stock, net of commissions and underwriter fees | ||||||
- | - | - | - | 137,220 | - | |
Proceeds from issuance of common stock, net of commissions and underwriter fees | ||||||
24,394 | 27,463 | 14,587 | - | - | - | |
Repurchase, early exercised stock | ||||||
- | - | - | - | - | 6 | |
Proceeds from public offering, net of commission | ||||||
- | - | - | - | - | 36,897 | |
Payments for common stock issuance costs | ||||||
171 | 345 | 93 | 189 | 2,153 | 2,617 | |
Issuance of common stock private investment in public entitiy | ||||||
- | - | - | - | - | 19,750 | |
Payments on loans payable | ||||||
- | - | - | - | -18,067 | - | |
Cash paid for contingent consideration | ||||||
- | - | - | 3,000 | 15,166 | - | |
Net cash provided by financing activities | ||||||
- | - | - | - | 100,978 | 72,497 | |
Net cash provided by (used in) financing activities | ||||||
-13,673 | 23,471 | 14,632 | 21,895 | - | - | |
Effect of exchange rate on cash | ||||||
-9 | 27 | -42 | - | - | - | |
Effect of exchange rate on cash | ||||||
- | - | - | -131 | 74 | - | |
Net decrease in cash, cash equivalents and restricted cash | ||||||
-25,436 | -20,439 | 60,552 | 17,282 | - | - | |
Net increase (decrease) in cash and cash equivalents | ||||||
- | - | - | - | -31,261 | 27,111 | |
Supplemental disclosure of cash flow information | ||||||
Cash paid for interest | ||||||
3,965 | 2,966 | 2,911 | 1,057 | - | - | |
Cash paid for interest | ||||||
- | - | - | - | 942 | 357 | |
Supplemental disclosure of noncash investing and financing activities: | ||||||
Unpaid common stock issuance costs included in accounts payable | ||||||
- | 48 | - | - | - | - | |
Conversion of preferred stock into common stock | ||||||
- | - | - | - | - | 41,953 | |
Payment of dividends on preferred stock | ||||||
- | - | - | - | - | 4,535 | |
Contingent consideration relating to Okapi Sciences NV acquisition | ||||||
- | - | - | - | 15,166 | - | |
Note payable related to Okapi Sciences NV acquisition | ||||||
- | - | - | - | 15,134 | - | |
Non-cash exercise of warrants | ||||||
- | - | - | 750 | - | - | |